Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | TNKS | O95271 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17775994 | 0.78 | L3MBTL1 (0.39) | L3MBTL1NUDT1HCRTR1HCRTR2HTR4 | |
| SCHEMBL24995375 | 0.78 | L3MBTL1 (0.42) | L3MBTL1NUDT1HCRTR1HCRTR2HTR4 | |
| SCHEMBL26937867 | 0.77 | NUDT1 (0.50) | L3MBTL1NUDT1HCRTR1HCRTR2HTR2C | |
| SCHEMBL24529479 | 0.77 | HTR2C (0.47) | L3MBTL1NUDT1HTR2CTNKS | |
| SCHEMBL24996533 | 0.74 | — | — | |
| SCHEMBL27114743 | 0.74 | TNKS (0.36) | L3MBTL1NUDT1HCRTR1HCRTR2HTR4 | |
| SCHEMBL6936541 | 0.73 | L3MBTL1 (0.34) | L3MBTL1HCRTR1HCRTR2HTR4 | |
| SCHEMBL19520117 | 0.73 | NUDT1 (0.46) | L3MBTL1NUDT1TNKS | |
| SCHEMBL29297543 | 0.71 | TNKS (0.33) | L3MBTL1HCRTR1HCRTR2HTR4TNKS | |
| SCHEMBL27017631 | 0.68 | HTR4 (0.45) | HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10925876-B2 | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders | MERCK SHARP & DOHME CORP. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20190282579-A1 | METHODS FOR USING TRIAZOLO-PYRAZINYL SOLUBLE GUANYLATE CYCLASE ACTIVATORS IN FIBROTIC DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282579-A1 | METHODS FOR USING TRIAZOLO-PYRAZINYL SOLUBLE GUANYLATE CYCLASE ACTIVATORS IN FIBROTIC DISORDERS | GUCY1B1, GUCY1A1, GUCY1A2 | L3MBTL1 4446/4885NUDT1 1277/4885HCRTR1 3954/4885 |
| US-10925876-B2 | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders | GUCY1B1, GUCY1A1, GUCY1A2 | L3MBTL1 4446/4885NUDT1 1277/4885HCRTR1 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.